摘要
目的探讨唑来膦酸联合瑞舒伐他汀辅助治疗老年骨质疏松椎体压缩性骨折的临床观察。方法 108例老年压缩性骨折女性患者随机分为对照组和治疗组。两组患者均进行给予PVP结合抗骨质疏松药物唑来膦酸治疗,治疗组在术后加用瑞舒伐他汀治疗。分别在治疗前后12个月评定两组患者视觉模拟疼痛评分(VAS)及Oswestry功能障碍指数评分(ODI);治疗前后12个月检测患者骨密度及骨特异性碱性磷酸酶(BAP)和I型前胶原肽(CTX);观察两组患者药品不良反应及邻近椎体再骨折发生情况。结果治疗后12个月两组患者VAS与ODI评分均较治疗前有明显改善(P<0.05),且治疗组患者评分明显低于对照组(P<0.05)。治疗后12个月,治疗组患者骨密度较治疗前显著改善(P<0.05),血清BAP和CTX较术前明显下降(P<0.05),且均明显优于对照组(P<0.05)。两组药品不良反应发生率比较,差异无统计学意义(P>0.05);而邻近椎体再骨折发生率治疗组相对对照组明显降低,比较有统计学意义(P<0.05)。结论唑来膦酸联合瑞舒伐他汀治疗老年骨质疏松椎体压缩性骨折疗效较好,能增加患者骨密度,降低邻近椎体再骨折发生率,降低骨吸收水平,安全性好。
Objective To investigate the clinical observation of zoledronic acid combined with rosuvastatin in the treatment of senile osteoporotic vertebral compression fractures. Methods A total of 108 elder female patients with osteoporotic vertebral compression fractures were randomly divided into treatment group and control group. The patients in both groups received percutaneous vertebroplasty（PVP） and rosuvastatin treatment. The patients in treatment group received additionally 5 mg of zoledronic acid after the operation. The visual analogue scale（VAS） and Oswestry disability index score（ODI） were recorded before and 12 months after the treatment. Bone mineral density（BMD）,bone specific alkaline phosphatase（BAP）,and type I procollagen peptide（CTX） were measure before and 12 months after the treatment. The adverse drug reaction and the incidence of refracture were observed. Results The VAS and ODI scores improved in patients of both groups 12 months after the treatment（P〈0. 05）,and the scores in patients of treatment group was lower than those in control group（P〈0. 05）. In treatment group,BMD improved and the serum BAP and CTX decreased significantly 12 months after the treatment,compared with those before the treatment（P〈0. 05）,and all indexes were better than control group（P〈0. 05）. There was no statistical significance of the incidence of adverse drug reaction between the two groups（P〉0. 05）. The incidence of refracture in treatment group was significantly lower than in control group（P〈0. 05）. Conclusion The application of zoledronic acid combined with rosuvastatin has favorable curative effect on osteoporotic vertebral compression fractures in elderly female patients. It improves BMD,reduces the incidence of refracture and the level of bone resorption.
出处
《中国骨质疏松杂志》
CAS
CSCD
北大核心
2018年第3期353-357,共5页
Chinese Journal of Osteoporosis
